OTLK
Oncobiologics Inc is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing, manufacturing and commercializing complex biosimilar therapeutics in the disease areas of immunology and oncology.
Outlook Therapeutics, Inc. (OTLK) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Growth (C).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | C (2.3) | C (2.4) | C+ (2.7) | C+ (2.6) | C+ (2.5) |
| 2026-11-07 | C+ (2.5) | C (2.3) | C (2.4) | C (2.3) | C+ (2.7) | C (2.4) |
| 2026-10-31 | C+ (2.5) | C (2.2) | C (2.5) | C (2.4) | C+ (2.7) | C (2.5) |
| 2026-10-24 | C+ (2.5) | C (2.2) | C (2.5) | C (2.3) | A+ (5.0) | B- (2.9) |
| 2026-10-17 | C+ (2.5) | C (2.2) | C (2.4) | C (2.2) | A+ (5.0) | B- (2.9) |